Background: Variable rates of HER2 protein overexpression and gene amplification have been reported in advanced ovarian cancers (AOC). Trastuzumab, tested only as a single agent, has been shown to ...

What Is HER2-Positive Breast Cancer? HER2-positive breast cancer is when breast cancer cells have a protein receptor called human epidermal growth factor receptor 2 (HER2). Normally, this protein ...

Evaluate the efficacy and safety profiles of current and emerging HER2-directed therapies in NSCLC, and their potential impact on treatment paradigms. (Bazhenova) Describe the difference between ...

The potential to treat GEA by targeting HER2 was confirmed in 2010 when researchers showed that adding Roche’s Herceptin to chemotherapy extended OS from 11.1 months to 13.8 months.

The addition of pembrolizumab to trastuzumab and chemotherapy in patients with gastric cancer improved both progression-free and overall survival as compared with trastuzumab and chemotherapy alone.

Bayer and Boehringer Ingelheim both had new data on their HER2-targeting small-molecule drugs to present at the World Conference on Lung Cancer (WCLC), hoping to add new oral therapies to the ...

John Heymach, MD, PhD, The University of Texas MD Anderson Cancer Center, discusses exciting developments in HER2-targeted therapies that he foresees making a difference in the treatment of non ...

"As many as half of patients with HER2-positive breast cancer develop brain metastases, which often has a poorer prognosis than breast cancer that hasn't spread to the brain," says Nancy Lin ...

In this audio interview, Editor-in-Chief Eric Rubin and NEJM Evidence Associate Editor Oladapo Yeku discuss research being presented at the 2024 European Society of Medical Oncology annual meeting.